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Abstract
Background: Virtual screening in the form of similarity rankings is often applied in the early drug discovery process
to rank and prioritize compounds from a database. This similarity ranking can be achieved with structural similarity
measures. However, their general nature can lead to insufficient performance in some application cases. In this paper,
we provide a link between ranking-based virtual screening and fragment-based data mining methods. The inclusion
of binding-relevant background knowledge into a structural similarity measure improves the quality of the similarity
rankings. This background knowledge in the form of binding relevant substructures can either be derived by hand
selection or by automated fragment-based data mining methods.
Results: In virtual screening experiments we show that our approach clearly improves enrichment factors with both
applied variants of our approach: the extension of the structural similarity measure with background knowledge in the
form of a hand-selected relevant substructure or the extension of the similarity measure with background knowledge
derived with data mining methods.
Conclusion: Our study shows that adding binding relevant background knowledge can lead to significantly
improved similarity rankings in virtual screening and that even basic data mining approaches can lead to competitive
results making hand-selection of the background knowledge less crucial. This is especially important in drug discovery
and development projects where no receptor structure is available or more frequently no verified binding mode is
known and mostly ligand based approaches can be applied to generate hit compounds.
Keywords: Virtual screening, Structural similarity, Background knowledge, Data mining, Enrichment
Background
Medical needs are the starting point for every drug discov-
ery and development project. Apart from the classical in
vitro and in vivo studies used in this process, pharmaceuti-
cal research relies more andmore on in silicomethods like
(high throughput) virtual screening or molecular dock-
ing simulations [1,2]. Computational methods promise to
shorten the typically time-consuming efforts that come
with the development of new market-approved drug
compounds. In the early drug discovery process, vir-
tual screening is used to rank or select compounds from
huge databases of potential drug candidates that are later
assessed in wet-lab and animal studies. In case one or
more ligand structures of the target protein are known and
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available, virtual screening based on ligand similarities can
be used to calculate a ranking of candidate compounds in
a database. This approach is applied if no binding mode
of the reported ligands, as well as no X-ray or NMR
structure of the protein target is available and receptor
based approaches are not easily accessible. Yet even in
these cases the virtual screening approach is certainly
a valid orthogonal approach to derive interesting and
promising structures and scaffolds for the drug discovery
pipeline.
In this paper, we present a concept of how struc-
tural similarity based methods used in virtual screening
can be improved by integrating chemical background
knowledge in the form of binding relevant or informa-
tive structural elements. Improvement in this case means
higher enrichment of chemical compounds related to the
query compound in the similarity ranking of a com-
pound database. Consequently, more potentially biolog-
ically active and less potentially inactive compounds are
© 2013 Girschick et al.; licensee Chemistry Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Girschick et al. Journal of Cheminformatics 2013, 5:50 Page 2 of 22
http://www.jcheminf.com/content/5/1/50
selected in virtual screening for further processing in
the drug discovery pipeline (e.g. in vitro, in vivo). To
achieve an improved enrichment we extract binding rel-
evant substructures from known ligands and transform
them into a fingerprint. This fingerprint is then used
to extend a structural similarity measure. We present
two approaches to extract the binding relevant informa-
tion: first we use visual inspection of a known ligand as
well as literature review to identify binding relevant sub-
structures, second we test a relatively basic data mining
approach. We apply the Free Tree Miner (FTM) soft-
ware [3] that takes a set of two-dimensional chemical
structures as input. FTM mines for and returns all sub-
structures that occur frequently (more often than a user
defined minimum support threshold) in the given set.
These relevant substructures are then fragmented and the
fragments’ occurrences in a chemical structure are used
as bits in a binary occurrence fingerprint. A limitation
of the data mining based approach is the need for more
than one known ligand (active compound). An advantage
of the approach is that it can still be applied if no liter-
ature information on the binding relevant substructures
or structural patterns is available and that it saves human
effort.
In our experiments we extend two structural similar-
ity measures with background knowledge and apply them
to rank compounds in a database according to their sim-
ilarity to a known active structure. The first similarity
measure is based on the size of the maximum com-
mon substructure (MCS – e.g., Raymond et al. [4]) of
two molecules, the second is based on Extended Con-
nectivity Fingerprints (ECFP) [5]. No other factors like
drug-likeness, Cytochrome P450 interaction or physico-
chemical properties are used. This enables an isolated
view on the effects of the similarity methods used for the
rankings. The extended similarity measures are compared
to their non-extended versions to assess their perfor-
mance by calculating enrichment factors for 1%, 5% and
10% of the database.
We show that adding background knowledge on
important binding components of ligands to both, the
MCS similarity and the ECFP similarity, changes the
virtual screening ranking in such a way that the top
structures have improved docking scores, related struc-
tures are ranked at better positions and clearly improved
enrichment factor values are obtained. We also show that
replacing the visual inspection and literature search by
a data mining approach improves the similarity rankings
for most assessed data sets. The data mining approach
performs slightly weaker than the by-hand approach, but
gives competitive results.
The remainder of the paper is organized as follows: In
the next section we give detailed information on the data
and methods we use for the similarity calculations and
our experimental setup. This is followed by a presenta-
tion and discussion of our results before we conclude.
Additional result tables can be found in the Additional
file 1.
Materials andmethods
In this section we give detailed information on our experi-
mental setting, on howwe extend a similarity measure and
on the data sources and evaluation measures used in our
virtual screening experiments.
Experimental setup
When virtual screening by means of similarity ranking
is performed in a drug discovery project, the similarities
of all compounds in the screening database are calcu-
lated with respect to one or more known ligands of the
protein target (used as reference compounds). The com-
pounds in the database are subsequently sorted according
to their similarity scores in descending order so that the
compounds most similar to the reference appear first in
the ranking. A good similarity measure will find struc-
tures that are related to the reference – or that potentially
interact with the target protein – in the first few per-
cent of the list. To assess the performance of different
similarity measures we mix a set of known ligands into
a set of decoys to form a screening database. As ref-
erence compound for the similarity rankings we use a
randomly selected representative of the known ligands.
After applying the standard similarity ranking proce-
dure individually with each similarity measure, we can
evaluate the performance of the similarity measures by
examining the results for the known ligands in the screen-
ing database. The better a similarity measure is, the
more known ligands will be in the top section of the
ranking.
The experiments on extending a structural similarity
measure can be divided into two lines of experiments: line
“A” considers the by-hand selection of the binding relevant
information that is used to extend the similarity measure
Table 1 Overview of the steps necessary to apply the two
presented approaches to extend similarities
Step A: by-hand approach B: mining-based approach
1 Review literature/examine structure Calculate frequently occurring
to determine BI substructures (BI) in known
ligands with FTM
2 Fragment relevant substructure Build fingerprint from
and build binary occurrence frequently occurring
fingerprint from all fragments substructures
3 Rank DB with simext Rank DB with simext
Overview table of the steps necessary to apply the two presented approaches to
extend similarities. DB: database; BI: binding-relevant information.
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Table 2 Overview of the used DuD data sets
Protein PDB code Ligands Decoys Protein class minsup fp_length
HMGR [PDB:1HW8] 35 1242 other enzyme 0.9 66
ER [PDB:3ERT] 39 1399 nuclear hormone receptor 0.7 62
PPARγ [PDB:1FM9] 81 2910 nuclear hormone receptor 0.96 90
P38 MAP [PDB:1KV2] 234 8399 kinase 0.83 57
TK [PDB:1KIM] 22 785 kinase 0.9 74
FXa [PDB:1F0R] 142 5102 serine protease 0.8 81
ADA [PDB:1STW] 23 822 metalloenzyme 0.8 70
DHFR [PDB:3DFR] 201 7150 folate enzyme 0.8 70
AChE [PDB:1EVE] 105 3732 other enzyme 0.77 93
COX-2 [PDB:1CX2] 349 12491 other enzyme 0.6 65
Overview of the used DuD data sets.minsup gives the minimum support parameter used in the FTM calculations and fp_length the length of the resulting fingerprint.
and line “B” considers the data mining based selection of
this information.
Table 1 shows a comparison of the steps necessary to
apply the two presented approaches to extend similarity
measures and rank a screening database.
Extended similarity
The extended similarity measures proposed in this work
are constructed from two building blocks: a structural
similarity measure used as base simililarity (simbase) and
a fingerprint-based similarity that is based on the bind-
ing relevant substructures (simbind_ fp). After defining the
extended similarity measure we will first explain the
base similarities and second explain the two variants
used to derive simbind_ fp. The extended similarity of two
molecules a and b is defined as:
simext (a, b) = 1 − αsimbase (a, b) + αsimbind_ fp (a, b) ,
(1)
where simbind_ fp (a, b) gives the Tanimoto similarity coef-
ficient (for a mathematical definition see the Additional
file 1) of two binary sub-structural occurrence finger-
prints of molecules a and b.
For most experiments we choose α = 13 as weight
coefficient for the fingerprint-based part arbitrarily and
Figure 1 Overview of the experimental setup of the (A) by-hand extension experiments (B)mining-based extension experiments. The
upper half of the workflow shows a similarity ranking without the incorporation of background knowledge. FP = fingerprint.
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Figure 2 Atorvastatin. 2D structure depiction of Atorvastatin
(PubChem CID 60823).
motivated by the wish to weight the base similarity
higher than its extension. No optimization regarding
this parameter has been attempted, however we show
a short evaluation of α in the Results and discussion
section. In our experiments the substructures constitut-
ing the fingerprint for simbind_ fp are selected by visual
inspection and literature review or by a data mining
approach.
The first structural similarity measure (simbase) that we
extend is based on the notion of maximum common sub-
structures (MCS). For computation of the size of the MCS
Figure 3 Fluvastatin. 2D structure depiction of Fluvastatin
(PubChem CID 446155), the binding relevant substructure is marked.
Figure 4 Lovastatin. 2D structure depiction of Lovastatin (PubChem
CID 53232).
Figure 5Mevastatin. 2D structure depiction of Mevastatin
(PubChem CID 64715).
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of two molecular structures, the JChem Java classes were
used (JChem 5.4.0.0, ChemAxon (http://www.chemaxon.
com)). The similarity between two structures was then
calculated with the similarity measure proposed byWallis
et al. [6]:
simMCS (a, b) = |mcs (a, b)||a| + |b| − |mcs (a, b)| , (2)
where |·| gives the number of vertices in a graph, and
mcs(a, b) calculates the MCS of molecules a and b. Con-
sequently, |mcs (a, b)| is the number of atoms of the MCS
of molecules a and b. The second structural similarity
measure is based on Extended-Connectivity Fingerprints
(ECFP) [5], a standardmethod in pharmaceutical research
and industry. ECFP fingerprints are circular, structural
feature fingerprints that use as input information not
only the atom and bond type, but the six atom number-
ing independent Daylight atomic invariants [7] to encode
atoms: the number of immediate heavy atom neighbors,
the valence minus the number of hydrogens, the atomic
number, the atomic mass, the atomic charge, the number
of attached hydrogens, plus a seventh invariant added by
Rogers et al. [5]: whether the atom is contained in at least
one ring. These fingerprints are available via the RDKit
functionality of the open source cheminformatics soft-
ware AZOrange [8]. The radius parameter for the ECFP
fingerprint calculation was used at the default value of
r = 2. The fingerprint similarity of two ECFP fingerprints
is calculated with the Dice coefficient (for a mathematical
definition see the Additional file 1).
Our first approach (approach A) to extend simbase relies
on literature review or visual inspection of a set of known
ligands to retrieve a binding relevant substructure (or
fragment). Once such a substructure is known we apply
the Free Tree Miner [3] software without minimum fre-
quency constraint to produce all possible fragments of
the substructure. From these fragments we build a binary
Figure 6 Pitavastatin. 2D structure depiction of Pitavastatin
(PubChem CID 24848419).
occurrence fingerprint that is used to encode the reference
molecules and all database molecules. The fingerprints
are then used to calculate simbind_ fp. In our experimen-
tal evaluation of approach A on the HMGR data set, we
derive the binding relevant substructure not only by lit-
erature review (which would be the standard approach
and sufficient in most cases), but we support the pro-
cess by additional calculations. First, we use the MCS
similarity measure to rank the screening database. Subse-
quently, the top 25 compounds of the similarity ranking
are docked to the HMGR receptor. The examination of the
results in combination with the literature review is used
to derive the binding relevant structural parts that are
used as background knowledge. For the second data set
used to evaluate approach A (PPARγ ) we derive the bind-
ing relevant stubstructure from reviewing known ligands
from the DrugBank [9] database. We expect the PPARγ
hand-selection experiments to show less improvement
than those on HMGR as the binding relevant information
is selected with less effort.
In our second approach to extend simbase, the data
mining based approach - denoted approach B, we try to
substitute the by-hand selection of the additional knowl-
edge that is integrated into the similarity measure by
applying datamining techniques. To retrieve the substruc-
ture fingerprint used for the similarity measure extension
we calculate the set of frequently occurring substructures
Figure 7 Simvastatin. 2D structure depiction of Simvastatin
(PubChem CID 54454).
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Figure 8 Selected HMGR ligand binding poses. Only the active site of the receptor is shown. A: Fluvastatin receptor binding. Original position of
fluvastatin in the HMGR ([PDB:1HWI]) receptor. The hand-selected important fragment is marked in yellow. B: Best docking of best MCS similarity
search hit in the HMGR ([PDB:1HWI]) receptor. C: Best docking of best MCSext similarity search hit in the HMGR ([PDB:1HWI]) receptor.
from a set of known ligands with the FTM algorithm.
From those frequent substructures we build the binary
occurrence fingerprint used to encode our molecules and
used to calculate simbind_ fp. Two variant of input ligand
sets are tested: (B1) We use all available ligands for the
generation of the fingerprint fragments. The minimum
support parameter (minsup) for the FTM software was
chosen in such a way for each data set that it resulted in
approximately the same number of substructural features
as the fingerprint of approach A did (57 features). The
parameters are given in Table 2. This ensures that we can
exclude the lenght of the fingerprint (feature number) as
driving force of improvement or degradation. (B2) We use
only 10% (20% in case of the DuD HMGR, ADA and TK
data sets) of the ligand compounds randomly chosen from
the respective DuD ligand sets to work with a more real-
istic setting, where only few compounds interacting with
the protein are known in advance. The minimum sup-
port parameter of FTM was set to 0.9 for all data sets.
This second, reduced variant provides less information on
the ligands to be found in the ranking and consequently
poses a more realistic but harder problem. The result-
ing enrichment factor values of the extended similarity
measures should show less improvement over the non-
enxtended versions compared to the first variant that uses
all ligands.
For a graphical overview of the two extension ap-
proaches as well as how they interact with the base-line
similarity ranking please see Figure 1.
Data
In the first line of experiments (by-hand selection) we use
only two data sets for our analysis, in line two of the exper-
iments (data mining based extension) we use ten data sets
from the Directory of useful Decoys (DuD) [10] as well
as 25 ChEMBL activity class data sets [11]. We use dif-
ferent database setups in our evaluation: For experiments
with the DuD data sets we use either all 95,000 decoy
structures of the DuD (DuDall) or only those DuD decoys
as database that were designed especially for the target
ligand system considered (DuDset). For the experiments
with the ChEMBL activity classes we use a subset of the
ZINC [12] database.
HMGR and statins
In our approach A experiments we first consider the prob-
lem of inhibition of the enzyme HMG-CoA reductase
(HMGR). Well-known inhibitors of HMGR are chemi-
cals from the drug class of statins (HMG-CoA reduc-
tase inhibitors). Most of them are marketed drugs or
drugs under development. Inhibition of HMGR lowers
the cholesterol levels and prevents cardiovascular diseases
[13], which are a major problem in developed countries
as coronary artery disease affects 13 to 14 million adults
in the United States alone [14]. The statins are struc-
turally quite similar as can be seen in Figures 2, 3, 4, 5,
6 and 7. All of them are competitive inhibitors of
HMGR with respect to binding of the substrate HMG-
CoA, but not with respect to binding of NADPH [15].
The protein receptor used in the docking procedure
is the structure of HMGR co-crystallized with fluvas-
tatin (Figure 8, CID 446155), which is available in the
PDB [16] with identifier [PDB:1HWI] [17]. We use
two sets of known ligands that are mixed with the
decoys and provide the reference compound in this first
set of experiments: first the set of statins and second
Table 3 PPARγ market approved drugs









PPARγ market approved drugs with DrugBank ID and drug name.
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Figure 9 PPARγ approved active drugs. Eight DrugBank listed
PPARγ active drugs that have “approved” status. The DrugBank ID is
shown with the molecule.
the HMGR ligands provided by the DuD HMGR data
set. In case the statins are used as ligand set, we
repeat the experiment with each statin as query com-
pound, otherwise we randomly select ten DuD HMGR
ligands and use each one of those as query com-
pound.
PPARγ
In addition to HMGR we test the by-hand selection
approach on the PPARγ data set. The PPARγ recep-
tor binds peroxisome proliferators such as hypolipi-
demic drugs and fatty acids. Once activated by a ligand,
the receptor binds to a promoter element in the gene
for acyl-CoA oxidase and activates its transcription. It
therefore controls the peroxisomal beta-oxidation path-
way of fatty acids and is a key regulator of adipocyte
Table 4 Results of the docking run (MCS top 25)
Rank CID Score RankMCS RankMCS
1 60823 -10.564 2 -1
2 ZINC02336737 -5.808526 13 -11
3 ZINC00026851 -5.699634 19 -16
4 ZINC00588719 -5.568737 11 -7
5 ZINC00599752 -5.46502 5 0
6 ZINC00588053 -5.463745 16 -10
7 ZINC00864379 -5.291673 15 -8
8 ZINC01253780 -5.211104 14 -6
9 ZINC00714466 -5.149133 9 0
10 ZINC00588723 -5.14689 4 6
Results of the docking run (MCS top 25).Rank = Rankdocking − RankMCS . A
negativeRank value means, in the MCS similarity the compound is ranked
lower, a positiveRank that it is ranked higher than by the docking procedure.
For the complete table, refer to Additional file 1: Table S1.
Figure 10 ZINC26851. 2D structure depiction of ZINC26851 from
the MCS similarity ranking. Rank difference: Rank = −16.
Figure 11 ZINC588723. 2D structure depiction of ZINC588723 from
the MCS similarity ranking. Rank difference: Rank = 6.
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Figure 12 ZINC714466. 2D structure depiction of ZINC714466 from
the MCS similarity ranking. Rank difference: Rank = 0.
Figure 13 ZINC4628438. 2D structure depiction of ZINC4628438
from the MCS similarity ranking. Rank difference: Rank = 11.
Table 5 Results of the docking run (MCSext top 25)
Rank CID Score RankMCSext RankMCSext
1 ZINC00588723 -10.382184 16 -15
2 24848419 -7.980885 3 -1
3 ZINC01253780 -7.385909 9 -6
4 ZINC00625939 -7.157018 11 -7
5 ZINC01032240 -7.104563 5 0
6 ZINC00864379 -7.052449 10 -4
7 ZINC00026851 -6.910078 19 -12
8 ZINC00714466 -6.702119 6 2
9 ZINC01112466 -6.667553 7 2
10 64715 -6.654007 12 -2
Results of the docking run (MCSext top 25).Rank = Rankdocking − RankMCS or ECFP .
A negativeRank value means, in the extended similarity the compound is
ranked lower, a positiveRank that it is ranked higher than by the docking
procedure. For the complete table, refer to Additional file 1: Table S1.
differentiation and glucose homeostasis [18]. The Drug-
Bank [9] database lists - amongst others - these eight
drugs that are market approved and known PPARγ
interactors: Bezafibrate, Glipizide, Ibuprofen, Mesalazine,
Sulfasalazine, Balsalazide, Rosiglitazone and Pioglitazone.
An overview of the drugs, their DrugBank IDs and struc-
tures are given in Table 3 and Figure 9.
We use the same query and database set-up as with the
HMGR experiments.
Figure 14 ZINC599752. 2D structure depiction of ZINC599752 from
the extended MCS similarity ranking (MCSext). Rank difference:
Rank = 11.
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Directory of useful decoys
As database for the approach B experiments, we use the
Directory of useful Decoys that is designed to avoid bias in
docking and screening studies. TheDuD database consists
of more than 95,000 decoy structures and 2,950 ligand
structures (more than 30 decoy structures per ligand)
for 40 protein targets including HMGR. We chose eight
target structures from the DuD database in addition to
HMGR and PPARγ . The original forty DuD target sets
are grouped into six classes: nuclear hormone receptors,
kinases, serine proteases, metalloenzymes, folate enzymes
and other enzymes. We selected the additional protein
targets to cover all six classes: estrogen receptor (ER;
antagonists) from the class of nuclear hormone recep-
tors, p38 mitogen-activated protein kinase (P38 MAP)
and thymidine kinase (TK) for the class of kinases, fac-
tor Xa (FXa) for the class of serine proteases, adenosine
deaminase (ADA) for the class of metalloenzymes, dihy-
drofolate reductase (DHFR) for the class of folate enzymes
and the acetylcholine esterase (AChE) as well as cyclooxy-
genase 2 (COX-2) for the remaining “other enzyme” class.
An overview of the DuD data sets used in this study
is given in Table 2. For DHFR three and for FXa two
ECFP similarities could not be calculated due to software
problems (the applied RDKit software was not able to pro-
cess those molecules). The respective compounds were
removed from the experimental setting. For this second
set of experiments we randomly select ten of the ligands as
reference compounds and mix the remaining ligands with
the decoys. This procedure is repeated ten times.
Figure 15 ZINC1112466. 2D structure depiction of ZINC1112466
from the extended MCS similarity ranking (MCSext). Rank difference:
Rank = 2.
ChEMBL activity classes
To strengthen the findings on the mining-based exper-
iments with the DuD data sets we add another set of
compound data sets compiled by Li and Bajorath [11].
They selected compounds by activity class from the
ChEMBL database (ChEMBL level 9) with restrictions to
the reported potency values (at least 10μM) and the con-
tained number of distinct Bemis and Murcko scaffolds
[19] (at least 3). After evaluation they report 50 activity
classes as test cases for benchmark calculations. We use
25 (random selection) of those 50 activity classes (actu-
ally 49 – activity class 168 only provides one ligand and
is therefore removed) as ligand sets. We randomly select
ten ligands per activity class (or all available if the number
of compounds in the activity class is smaller than ten). As
background database we randomly select a set of 100,000
compounds from the ZINC [12] “All Purchasable” data
set. For this set of experiments we randomly select one of
the ligands as reference compound and mix the remaining
ligands with the decoys. This procedure is repeated ten
times.
Evaluation measures
To evaluate the performance of the similarity measures,
we consider the enrichment factor (EF) [20] that is
achieved by a virtual screening. The enrichment factor
Figure 16 ZINC4597014. 2D structure depiction of ZINC4597014
from the extended MCS similarity ranking (MCSext). Rank difference:
Rank = −12.
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Figure 17 ZINC19313623. 2D structure depiction of ZINC19313623 from the extended MCS similarity ranking (MCSext). Rank difference:
Rank = −2.
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Table 6 EF values for HMGR
Query vs. DB
MCS MCSext
1% 5% 10% 1% 5% 10%
stat vs DuDall 63.5 ± 14.1 10.1 ± 3.7 4.5 ± 2.3 16.7 ± 18.3 0.0 ± 0.0 0.0 ± 0.0
stat vs DuDset 61.2 ± 13.6 9.4 ± 4.4 3.1 ± 2.2 28.9 ± 26.1 1.7 ± 1.8 0.0 ± 0.0
lig vs DuDall 14.1 ± 1.7 1.1 ± 0.3 0.0 ± 0.1 3.1 ± 0.7 0.3 ± 0.1 0.0 ± 0.0
lig vs DuDset 0.0 ± 0.0 2.1 ± 0.5 0.0 ± 0.0 0.0 ± 0.0 1.7 ± 0.2 0.0 ± 0.0
ECFP ECFPext
1% 5% 10% 1% 5% 10%
stat vs DuDall 50.0 ± 0.0 10.0 ± 0.0 5.0 ± 0.0 8.3 ± 20.4 1.7 ± 0.0 0.0 ± 0.0
stat vs DuDset 52.0 ± 0.0 10.1 ± 0.0 5.0 ± 0.0 20.2 ± 20.2 0.0 ± 0.0 0.0 ± 0.0
lig vs DuDall 6.1 ± 1.2 1.4 ± 0.2 0.1 ± 0.1 5.9 ± 1.5 1.4 ± 0.3 0.0 ± 0.0
lig vs DuDset 0.1 ± 0.1 0.9 ± 0.2 0.0 ± 0.0 0.0 ± 0.0 0.4 ± 0.1 0.0 ± 0.0
EF value for all four similarity methods for the hand-selection experiments with HMGR at 1%, 5% and 10% of the database. Improvements compared to the
non-extended variant are marked in bold print. stat = statines.
reflects the amount of known related structures in the
first x% of the ranked database. In practice, often only
the highest ranked compounds are of interest and con-
sidered further in the drug discovery pipeline. The





where EF(%) is given for the specified percentage of the
ranked database, Nactive(%) is the number of active com-
pounds in the selected subset of the ranked database,N(%)
is the number of compounds in the subset, Nactive is the
number of active molecules in the data set and Nall is the
number of compounds in the database. For an easier inter-
pretation of the EF values, it is helpful to compare them
to the maximum possible enrichment at the specified
fraction of the database:
For easier comparison we do not use the EF(%) directly,
but the difference of maximum possible enrichment and
achieved enrichment:
EF = EFmax − EF(%). (4)
Keep in mind that for EF smaller values are better and
the optimal EF is zero. In our study, we use the top 1%,
5% and 10% fractions of the ranked database to calculate
the EF values. In the results section of this work we restrict
ourselves to showing the EF values.
Docking procedure
Molecular docking was applied in order to assess if the
extensions to the structural similarity measures are suit-
able for virtual screening. For the HMGR experiments we
did the docking ourselves, for the second experiment we
used the docking scores as provided in the DuD database.
We now describe the docking procedure applied in the
by-hand HMGR experiment.
HMGR is a tetra-mer with four identical binding sites
whereas two chains contribute residues to one binding
site. In the PDB six co-crystallizations of HMGR are avail-
able, each with one statin: atorvastatin ([PDB:1HWK]),
fluvastatin ([PDB:1HWI]), simvastatin ([PDB:1HW9]),
compactin ([PDB:1HW8]), rosuvastatin ([PDB:1HWL])
and cerivastatin ([PDB:[1HWJ]). A comparison of the
CoA bound binding sites with the statin bound binding
sites showed rearrangements. In the statin bound bind-
ing sites some residues are disordered which fold to an
α-helix when CoA is bound. In the presence of the α-helix,
a narrow pantothenic acid-binding pocket is formed mak-
ing it impossible for statins to bind. Instead a hydrophobic
groove is formed that accommodates the hydrophobic
moieties of the statins which accounts for a tighter bind-
ing of the statins [17]. Since we are interested in drug
candidates with a similar binding ability as the statins, we
focus on the statin bound HMGR structures. According
to Istvan et al. [17] the orientation of the side chains in
the binding sites does not differ among the statins. This
was confirmed by a superposition of the six PDB struc-
tures with Pymol (http://www.pymol.org/). Due to this
we chose to perform a rigid receptor cross-docking of
the structural similar drug candidates to 1hwi with Glide
5.7 from the Maestro Suite of Schrödinger. If not indi-
cated otherwise, the default settings were used. The first
step in the docking process was the automatic preparation
of the complete PDB structure of [PDB:1HWI] with the
Protein Preparation Wizard of the Maestro Suite. Since
there are four identical binding sites, the docking was
performed with only one of them. At some binding sites
ADP is bound nearby. Since ADP does not participate
in statin binding [17] the binding site mainly formed by
chain D with some contribution of chain C was chosen,
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Figure 18 PPARγ binding relevant substructures. Binding relevant substructures used for calculating the bind_fp fingerprint for the PPARγ
by-hand experiments (approach A).
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Table 7 EF values for PPAR γ
Query vs. DB
MCS MCSext
1% 5% 10% 1% 5% 10%
ChBa vs DuDall 82.9 ± 6.5 15.0 ± 1.3 7.0 ± 1.1 79.7 ± 6.5 15.0 ± 1.9 7.3 ± 0.8
ChBa vs DuDset 73.8 ± 10.5 12.2 ± 3.4 5.2 ± 1.6 80.0 ± 6.5 14.4 ± 1.8 7.0 ± 0.9
lig vs DuDall 10.3 ± 5.7 7.9 ± 3.3 4.1 ± 2.7 11.0 ± 6.1 8.2 ± 7.5 2.9 ± 2.8
lig vs DuDset 8.2 ± 3.6 6.9 ± 2.8 3.0 ± 2.3 8.0 ± 6.1 7.0 ± 9.5 1.9 ± 2.6
ECFP ECFPext
1% 5% 10% 1% 5% 10%
ChBa vs DuDall 79.7 ± 9.3 13.8 ± 1.9 6.6 ± 0.6 78.1 ± 8.8 14.7 ± 1.6 7.0 ± 0.9
ChBa vs DuDset 70.7 ± 11.5 12.9 ± 1.6 5.5 ± 1.9 78.5 ± 8.9 14.1 ± 2.3 6.7 ± 1.1
lig vs DuDall 6.9 ± 3.3 7.4 ± 11.1 2.4 ± 2.6 10.0 ± 8.3 4.6 ± 1.1 1.2 ± 1.2
lig vs DuDset 4.2 ± 2.1 6.1 ± 1.3 0.9 ± 1.1 3.9 ± 8.7 3.5 ± 1.9 0.9 ± 0.7
EF value for all four similarity methods for the hand-selection experiments with PPARγ at 1%, 5% and 10% of the database. Improvements compared to the
non-extended variant are marked in bold print. ChBa = ChemBank ligands.
Table 8 MeanEF and standard deviation for theMCS andMCSext similarity methods (approach B1)
DuD set
MCS MCSext
1% 5% 10% 1% 5% 10%
HMGR 8.5 ± 4.5 7.0 ± 6.8 2.8 ± 3.6 4.6 ± 9.8 2.0 ± 1.0 0.5 ± 0.3
ER 13.6 ± 7.6 12.6 ± 4.1 5.3 ± 1.7 13.1 ± 7.0 11.4 ± 2.8 3.7 ± 0.9
PPARγ 4.6 ± 10.6 1.2 ± 5.4 1.7 ± 2.8 4.6 ± 11.0 3.8 ± 5.5 1.5 ± 2.9
P38 MAP 9.6 ± 7.9 8.6 ± 3.7 3.3 ± 1.8 3.8 ± 5.4 4.8 ± 4.2 2.4 ± 2.1
TK 20.1 ± 4.4 12.6 ± 2.1 5.1 ± 1.6 18.3 ± 5.3 12.3 ± 2.7 4.0 ± 1.3
FXa 4.6 ± 11.2 7.6 ± 3.8 3.3 ± 1.8 3.5 ± 11.0 6.4 ± 4.6 2.5 ± 2.5
ADA 10.1 ± 6.4 8.2 ± 3.0 4.3 ± 3.6 9.2 ± 4.8 7.7 ± 2.0 2.3 ± 0.8
DHFR 10.9 ± 10.6 11.7 ± 2.9 4.7 ± 1.1 3.1 ± 5.0 0.3 ± 0.3 0.0 ± 0.0
AChE 10.3 ± 12.5 11.3 ± 4.7 4.8 ± 2.5 10.0 ± 11.8 9.5 ± 5.8 4.4 ± 3.0
COX-2 12.3 ± 9.2 11.7 ± 2.2 5.3 ± 1.1 10.7 ± 10.3 10.1 ± 3.8 2.2 ± 2.6
w/d/l 10 / 0 / 0 9 / 0 / 1 10 / 0 / 0
MeanEF and standard deviation for the MCS and MCSext similarity methods at 1%, 5% and 10% of the database (receptor specific decoy set DuDset ). The extension
fingerprint is calculated from all ligands (approach B1). Improvements of MCSext compared to MCS are marked with bold print. w/d/l = wins/draws/losses.
Table 9 MeanEF and standard deviation for the ECFP and ECFPext similarity methods (approach B1)
DuD set
ECFP ECFPext
1% 5% 10% 1% 5% 10%
HMGR 8.7 ± 9.4 6.8 ± 8.5 4.2 ± 5.6 0.0 ± 0.0 2.8 ± 2.2 0.9 ± 0.5
ER 8.0 ± 4.0 7.4 ± 3.9 6.7 ± 4.6 6.3 ± 4.8 9.2 ± 1.6 3.3 ± 1.2
PPARγ 1.3 ± 0.7 7.1 ± 11.2 1.0 ± 0.7 4.2 ± 11.1 3.6 ± 5.7 1.8 ± 2.8
P38 MAP 7.0 ± 5.9 5.9 ± 3.0 3.4 ± 2.0 2.8 ± 5.7 5.0 ± 4.1 2.4 ± 2.1
TK 9.8 ± 6.0 12.1 ± 8.9 10.9 ± 6.4 16.5 ± 8.4 11.4 ± 3.6 4.3 ± 2.0
FXa 7.4 ± 11.3 2.4 ± 2.0 1.7 ± 1.5 3.5 ± 11.0 4.3 ± 5.3 2.0 ± 2.7
ADA 6.3 ± 3.3 6.4 ± 4.5 8.9 ± 6.0 8.3 ± 7.1 7.7 ± 2.0 2.4 ± 1.0
DHFR 2.5 ± 2.0 1.8 ± 1.5 1.8 ± 1.5 1.9 ± 0.9 0.1 ± 0.1 0.0 ± 0.0
AChE 15.0 ± 11.2 5.2 ± 2.3 6.8 ± 3.8 11.0 ± 12.0 9.4 ± 5.6 4.0 ± 2.8
COX-2 8.7 ± 10.6 3.4 ± 1.9 3.4 ± 2.5 6.7 ± 10.0 5.5 ± 5.0 2.1 ± 2.6
w/d/l 7 / 0 / 3 5 / 0 / 5 8 / 0 / 2
MeanEF and standard deviation for the ECFP and ECFPext similarity methods at 1%, 5% and 10% of the database (receptor specific decoy set DuDset ). The extension
fingerprint is calculated from all ligands (approach B1). Improvements of ECFPext compared to ECFP are marked with bold print. w/d/l = wins/draws/losses.
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Table 10 MeanEF and standard deviation for the bind_fp




HMGA 6.7 ± 1.5•◦ 1.1 ± 0.0•◦ 0.6 ± 0.0•◦
ER 62.3 ± 15.2 8.7 ± 4.1◦ 2.7 ± 1.6•◦
PPARγ 13.2 ± 30.1 2.4 ± 6.1 1.2 ± 3.0◦
P38 MAP 24.2 ± 22.2 4.8 ± 4.3◦ 2.4 ± 2.1•◦
TK 42.8 ± 24.3 0.9 ± 1.5•◦ 0.0 ± 0.0•◦
Fxa 21.2 ± 26.9 3.8 ± 5.5◦ 1.8 ± 2.7◦
ADA 26.1 ± 0.0 1.7 ± 0.0•◦ 0.5 ± 0.1•◦
DHFR 0.0 ± 0.0•◦ 0.0 ± 0.0•◦ 0.0 ± 0.0•◦
AchE 47.4 ± 34.8 7.7 ± 6.0◦ 3.8 ± 3.0•◦
COX-2 71.6 ± 22.6 10.2 ± 6.3◦ 2.2 ± 2.6•◦
MeanEF and standard deviation for the bind_fp similarity method at 1%, 5%
and 10% of the database (receptor specific decoy set DuDset ). The extension
fingerprint is calculated from all ligands (approach B1). Cases where bind_fp is
better than ECFP or MCS are marked with a • or ◦ , respectively.
which lacks ADP. In order to speed up the docking pro-
cedure, the multi-mer was simplified by removing the
redundant chains A and B. The receptor preparation was
completed by the manual removal of all waters, the ligand
molecule and the ADPs of the other binding site formed
by chain C and D. The selected drug candidates were pre-
pared using Ligprep 2.5. In a preprocessing step of the
docking procedure the receptor grid for the chosen bind-
ing site was pre-calculated using the Glide 5.7 Receptor
Grid Generation. The co-crystallized fluvastatin in the
chosen binding site was used as reference ligand. Subse-
quently the rigid receptor docking was performed with




In the first set of experiments we extract the binding-
relevant knowledge used to extend the structural sim-
ilarity measures by literature review and support the
process by MCS similarity ranking and docking calcula-
tions.We therefore rank the screening database (including
decoys and statin ligands) with respect to fluvastatin using
simMCS. Subsequently, we docked the top 25 compounds
of the similarity ranking to the HMGR receptor. Looking
at the docking results in Table 4 (and the long version in
the Additional file 1: Table S1), it can be seen that only
one compound (CID 60823) has a good docking score.
This is atorvastatin, one of the two statins found in the top
25 of the MCS similarity ranking. All other compounds
have rather weak docking scores. Four structures from
this ranking are shown in Figures 10, 11, 12, 13 and the
docking of the best non-statin is shown in Figure 8B. It
can clearly be seen that the highlighted part of the struc-
ture of fluvastatin (Figure 3 and Figure 8A) or something
structurally similar, is not present in any of the structures
(non-statins). According to Istvan et al. [17], this part
mimics the original binding ligand and consequently is
essential for binding. The hydrophobic part of the statins
is responsible for the nano-molar affinity of the statins
but not sufficient for inhibitory binding on its own. Tak-
ing those facts into consideration, we decided to use the
highlighted hydrophilic part of fluvastatin as background
knowledge in our study. As described in the Materials and
methods Section, the substructure was fragmented and
Table 11 MeanEF values and standard deviations for theMCS andMCSext similarity methods (approach B2)
DuD set
MCS MCSext
1% 5% 10% 1% 5% 10%
HMGR 8.5 ± 4.5 7.0 ± 6.8 2.8 ± 3.6 9.1 ± 2.5 6.5 ± 6.1 2.0 ± 2.8
ER 13.6 ± 7.6 12.6 ± 4.1 5.3 ± 1.7 10.2 ± 6.5 10.6 ± 2.5 5.0± 1.0
PPARγ 4.6 ± 10.6 1.2 ± 5.4 1.7 ± 2.8 4.5 ± 11.0 3.8 ± 5.5 1.6± 2.9
P38 MAP 9.6 ± 7.9 8.6 ± 3.7 3.3 ± 1.8 7.1 ± 6.8 7.3 ± 3.7 2.7 ± 2.0
TK 20.1 ± 4.4 12.6 ± 2.1 5.1 ± 1.6 19.7 ± 5.3 14.0 ± 2.1 5.5 ± 1.5
FXa 4.6 ± 11.2 7.6 ± 3.8 3.3 ± 1.8 3.5 ± 11.2 6.2 ± 4.7 2.5 ± 2.6
ADA 10.1 ± 6.4 8.2 ± 3.0 4.3 ± 3.6 12.8 ± 6.4 8.8 ± 3.3 6.1 ± 4.6
DHFR 10.9 ± 10.6 11.7 ± 2.9 4.7 ± 1.1 3.4 ± 7.0 2.4 ± 2.1 0.1 ± 0.1
AChE 10.3 ± 12.5 11.3 ± 4.7 4.8 ± 2.5 10.1 ± 11.9 10.4 ± 5.1 4.4 ± 3.0
COX-2 12.3 ± 9.2 11.7 ± 2.2 5.3 ± 1.1 11.4 ± 10.3 10.5 ± 3.7 2.5 ± 2.5
w/d/l 8 / 0 / 2 7 / 0 / 3 8 / 0 / 2
MeanEF and standard deviations for the MCS and MCSext similarity methods at 1%, 5% and 10% of the database (receptor specific decoy set DuDset). The extension
fingerprint is calculated from 10% (20% for HMGR, TK and ADA) of the ligands (approach B2). Improvements of MCSext compared to MCS are marked with bold print.
w/d/l = wins/draws/losses.
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Table 12 MeanEF values and standard deviations for the ECFP and ECFPext similarity methods (approach B2)
ECFP ECFPext
DuD set 1% 5% 10% 1% 5% 10%
HMGR 8.7 ± 9.4 6.8 ± 8.5 4.2 ± 5.6 4.3 ± 9.5 6.5 ± 4.8 2.9 ± 2.6
ER 8.0 ± 4.0 7.4 ± 3.9 6.7 ± 4.6 6.8 ± 7.8 9.6 ± 2.5 4.4 ± 1.4
PPARγ 1.3 ± 0.7 7.1 ± 11.2 1.0 ± 0.7 4.2 ± 11.0 3.6 ± 5.6 1.8 ± 2.8
P38 MAP 7.0 ± 5.9 5.9 ± 3.0 3.4 ± 2.0 4.0 ± 6.0 7.0 ± 3.6 3.0 ± 1.9
TK 9.8 ± 6.0 12.1 ± 8.9 10.9 ± 6.4 18.8 ± 7.3 11.8 ± 3.8 4.9 ± 2.0
FXa 7.4 ± 11.3 2.4 ± 2.0 1.7 ± 1.5 3.5 ± 11.2 4.5 ± 5.3 2.0 ± 2.7
ADA 6.3 ± 3.3 6.4 ± 4.5 8.9 ± 6.0 8.3 ± 7.1 9.3 ± 2.0 4.4 ± 1.1
DHFR 2.5 ± 2.0 1.8 ± 1.5 1.8 ± 1.5 5.7 ± 5.5 0.5 ± 0.8 0.0 ± 0.0
AChE 15.0 ± 11.2 5.2 ± 2.3 6.8 ± 3.8 12.2 ± 12.7 10.0 ± 5.4 4.6 ±2.9
COX-2 8.7 ± 10.6 3.4 ± 1.9 3.4 ± 2.5 6.8 ± 10.2 5.4 ± 4.9 2.0 ± 2.7
w/d/l 6 / 0 / 4 4 / 0 / 6 8 / 0 / 2
MeanEF and standard deviations for the ECFP and ECFPext similarity methods at 1%, 5% and 10% of the database (receptor specific decoy set DuDset). The extension
fingerprint is calculated from 10% (20% for HMGR, TK and ADA) of the ligands (approach B2). Improvements of ECFPext compared to ECFP are marked with bold print.
w/d/l = wins/draws/losses.
used to derive a binary occurrence fingerprint of length 57
for the extended similarity measure (1).
We then calculated a similarity ranking with the
extended MCS similarity measure and again docked the
top 25 compounds. The results of docking the top 25
compounds of the extended MCS similarity ranking are
shown in Table 5 (see Additional file 1: Table S2 of the
supplement). Four structures from the ranking are shown
in Figures 14, 15, 16 and 17. The docking scores are
clearly improved in comparison to those of the structures
found by the MCS similarity ranking given in Table 4 (see
Additional file 1: Table S1). This means that the com-
Table 13 MeanEF and standard deviation for the bind_fp
similarity method (approach B2)
Bind_fp
DuD set 1% 5% 10%
HMGR 36.5 ± 2.0 20.2 ± 3.2 10.0 ± 2.2
ER 36.8 ± 11.2 20.2 ± 6.0 10.0 ± 3.9
PPARγ 34.3 ± 5.4 19.6 ± 4.1 6.8 ± 2.3
P38 MAP 20.0 ± 0.0 17.3 ± 6.8 8.6 ± 1.4
TK 36.6 ± 13.7 20.2 ± 12.0 10.1 ± 4.2•
FXa 9.9 ± 7.6 8.5 ± 0.0 4.2 ± 0.8
ADA 36.7 ± 8.5 20.1 ± 0.0 10.0 ± 0.9
DHFR 36.5 ± 16.8 20.0 ± 7.9 10.0 ± 1.0
AChE 36.4 ± 6.9 20.1 ± 9.2 10.0 ± 3.2
COX-2 35.7 ± 7.5 19.8 ± 6.2 9.9 ± 1.0
MeanEF and standard deviation for the bind_fp similarity method at 1%, 5%
and 10% of the database (receptor specific decoy set DuDset). The extension
fingerprint is calculated from 10% (20% for HMGR, TK and ADA) of the ligands
(approach B2). Cases where bind_fp is better than ECFP or MCS are marked with
a • or ◦ , respectively.
pounds found will very likely have a higher binding affinity
to the receptor. Figures 8, 9 and 10 show the original posi-
tion of fluvastatin and dockings of the two non-statins
with the best docking score from the two similarity rank-
ings. It can be seen that the ligand of the extended MCS
similarity (in Figure 10) enters the active site much better
than the one of the MCS similarity (in Figure 9).
As last experiment for the by-hand approach, we cal-
culated similarity rankings with the ECFP similarity and
also with an extended version of the ECFP similarity.
We use the same binding-relevant substructure as for the
MCS similarity. Comparing the differences in enrichment
factors of the ligand structures in the ranked databases
Table 14 Best α coefficients for theMCSext and ECFPext
similarity methods (approach B2)
DuD set
ECFPext MCSext
1% 5% 10% 1% 5% 10%
HMGR 0.2 0.5 0.9 0.3 0.7 0.8
ER 0.1 0.3 0.2 0.6 0.6 0.5
PPARγ 0.1 0.4 0.0 0.0 0.4 0.0
P38 MAP 0.3 0.5 1.0 0.7 0.8 1.0
TK 0.0 0.1 0.3 0.3 1.0 0.2
Fxa 0.0 0.3 0.2 0.2 0.7 0.6
ADA 0.3 1.0 1.0 0.3 1.0 1.0
DHFR 0.1 0.3 0.5 0.4 1.0 0.6
AchE 0.2 0.3 0.1 0.2 0.3 0.4
COX-2 0.1 0.2 0.2 0.1 1.0 0.6
The best α coefficients for the MCSext and ECFPext similarity methods. α has
been increased from 0.0 to 1.0 in steps of 0.1. The coefficient giving the bestEF
value is reported. If two values are identical the smaller α is reported.
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Table 15 MeanEF and standard deviation using the best α coefficients (approach B1)
MCSext ECFPext
DuD set 1% 5% 10% 1% 5% 10%
HMGR 5.8 ± 10.0 1.7 ± 0.7 0.6 ± 0.3 0.6 ± 1.9 2.6 ± 3.2 0.6 ± 0.1
ER 12.1 ± 6.0 9.3 ± 3.5 3.2 ± 1.1 6.0 ± 5.3 8.5 ± 2.1 3.1 ± 1.2
PPARγ 4.5 ± 10.6 3.8 ± 5.5 1.5 ± 2.9 4.1 ± 10.7 3.6 ± 5.6 1.7 ± 2.5
P38 MAP 2.8 ± 6.9 4.8 ± 4.2 2.4 ± 2.1 2.7 ± 6.0 4.8 ± 4.2 2.4 ± 2.1
TK 18.3 ± 5.3 11.1 ± 3.8 3.7 ± 1.7 16.5 ± 8.4 11.1 ± 3.8 4.2 ± 1.9
FXa 3.5 ± 11.0 4.3 ± 5.4 2.0 ± 2.7 3.5 ± 11.0 4.2 ± 5.4 2.0 ± 2.7
ADA 9.2 ± 4.6 5.2 ± 0.0 2.2 ± 0.8 7.8 ± 7.5 5.2 ± 0.0 2.2 ± 0.7
DHFR 2.7 ± 5.1 0.0 ± 0.0 0.0 ± 0.0 1.9 ± 0.9 0.0 ± 0.0 0.0 ± 0.0
ACHE 10.0 ± 11.8 9.0 ± 6.0 4.3 ± 2.8 11.0 ± 12.0 9.0 ± 6.1 4.0 ± 2.8
COX-2 9.9 ± 9.8 9.8 ± 3.7 2.1 ± 2.6 6.7 ± 10.2 5.3 ± 5.0 2.1 ± 2.6
w/d/l 10 / 0 / 0 9 / 0 / 1 10 / 0 / 0 8 / 0 / 2 6 / 0 / 4 8 / 0 / 2
MeanEF and standard deviation using the best α coefficients for extended similarites MCSext and ECFPext for the receptor specific decoy sets DuDset at 1%, 5% and
10% of the database. The extension fingerprint is calculated from all ligands (approach B1). Improvements of MCSext compared to MCS as well as ECFPext compared to
ECFP are marked in bold print. w/d/l = wins/draws/losses.
(MCS and ECFP similarity rankings) with the respec-
tive extended variants (see Table 6), it is clear that the
extension is beneficial in all cases. Especially the MCS
similarity, that shows a slightly weaker performance than
the ECFP similarity, benefits from the similarity exten-
sion. Here an improvement of EF can be seen in all
except one cases (if further improvement is possible). For
ECFP a decrease in EF can be seen in all except four
cases.
For the second data set we use for testing the by-hand
approach, PPARγ , we shorten the selection procedure. By
visual inspection of the eight approved drugs shown in
Table 3 and Figure 9 as well as binding information on
Rosiglitazone given in by Liberato et al. [21] we select
two binding relevant substructures as shown in Figure 18.
As described in the Materials and methods Section, the
substructures were fragmented and used to derive a
binary occurrence fingerprint for the extended similarity
measure (1). The results for the similarity rankings that
are calculated in analogy to the HMGR by-hand experi-
ments are given in Table 7. The results clearly show that
the reduced effort to extract the binding-relevant infor-
mation has direct impact on the ranking performance.
Only in half of the settings (MCS lig vs. DUDset, ECFP
lig vs. DUDall and ECFP lig vs. DUDset) we see improve-
ments of the extended similarity measures in comparison
the base similarity measures. From that we conclude that
it is of high importance to be very careful on selecting the
Table 16 MeanEF and standard deviation using the best α coefficients (approach B2)
MCSext ECFPext
DuD set 1% 5% 10% 1% 5% 10%
HMGR 6.1 ± 10.5 2.1 ± 0.9 0.8 ± 0.4 2.7 ± 6.8 4.3 ± 5.6 1.5 ± 2.5
ER 8.1 ± 6.1 10.4 ± 2.9 4.6 ± 1.5 6.3 ± 5.4 10.0 ± 2.0 4.2 ± 1.3
PPARγ 4.6 ± 10.6 3.9 ± 5.5 1.7 ± 2.8 4.1 ± 10.7 3.5 ± 5.6 1.7 ± 2.5
P38 MAP 5.4 ± 6.4 5.4 ± 3.4 1.4 ± 0.1 3.9 ± 5.7 6.7 ± 3.8 1.4 ± 0.1
TK 17.4 ± 5.2 11.4 ± 4.8 4.7 ± 1.6 16.5 ± 8.4 11.4 ± 3.5 4.6 ± 2.1
FXa 3.5 ± 11.2 5.7 ± 5.1 2.5 ± 2.6 3.5 ± 11.0 5.0 ± 5.2 2.2 ± 2.6
ADA 9.7 ± 5.4 7.2 ± 2.6 2.4 ± 1.1 7.3 ± 7.2 6.9 ± 2.7 2.4 ± 1.0
DHFR 3.0 ± 6.0 0.8 ± 1.6 0.0 ± 0.0 2.4 ± 1.2 0.4 ± 0.9 0.0 ± 0.0
ACHE 10.1 ± 12.0 9.6 ± 5.8 4.5 ± 2.9 11.2 ± 12.2 9.4 ± 5.9 4.4 ± 2.8
COX-2 12.0 ± 10.3 10.8 ± 6.3 2.8 ± 2.8 6.7 ± 10.3 5.5 ± 4.9 2.2 ± 2.6
w/d/l 9 / 1 / 0 9 / 0 / 1 9 / 1 / 0 8 / 0 / 2 4 / 0 / 6 8 / 0 / 2
MeanEF and standard deviation using the best α coefficients for extended similarites MCSext and ECFPext for the receptor specific decoy sets DuDset at 1%, 5% and
10% of the database. The extension fingerprint is calculated from 10% (20% for HMGR, TK and ADA) of the ligands (approach B2). Improvements of MCSext compared
to MCS as well as ECFPext compared to ECFP are marked in bold print. w/d/l = wins/draws/losses.
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Figure 19 Plot of α vs. MeanEF for MCSext. On the x-axis the values of the combining factor α is plottet versus the mean EF for MCSext on the
y-axis. (approach B2).
Figure 20 Plot of α vs. MeanEF for ECFPext. On the x-axis the
values of the combining factor α is plottet versus the mean EF for
MCSext on the y-axis. (approach B2).
binding-relevant structural information when using the
presented approach A (by-hand selection).
Mining-based experiments
In the following, we first assess for both data-mining
based variants (B1: all known ligands used to calculate
the fragment occurrence fingerprint or B2: only part
of them used), if the extension of the MCS and the
ECFP similarity measures with the data mining derived
fingerprint improves the quality of the similarity ranking.
Second we compare the data mining approach with the
by-hand approach for the HMGR data set. The results for
variant B1 are given in Tables 8, 9 and 10. To see how
the data mining based approach performs, when only few
ligand structures are available as background knowledge,
we re-ran the experiments with variant B2: using only ten
per cent randomly chosen from the respective DuD ligand
sets (20% due to smaller ligand set sizes in case of the
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Table 17 Win/loss counts for ten random folds for extended similarites on DuD set (α = 0.3; approach B1)
ECFPext MCSext
1% 5% 10% 1% 5% 10%
Win Loss Win Loss Win Loss Win Loss Win Loss Win Loss
HMGR 10 0 10 0 10 0 5 0 5 0 5 0
ER 8 2 10 0 9 1 10 0 10 0 10 0
PPARγ 9 1 9 1 9 1 9 1 10 0 9 1
P38 MAP 9 1 10 0 10 0 10 0 10 0 9 1
TK 10 0 9 1 8 2 9 1 9 1 9 1
FXa 10 0 9 1 9 1 10 0 9 1 9 1
ADA 10 0 6 4 10 0 8 1 8 1 8 1
DHFR 8 2 10 0 10 0 10 0 10 0 10 0
ACHE 9 1 9 1 9 1 10 0 10 0 9 1
COX-2 6 4 7 3 8 2 7 3 9 1 9 1
Sum 89 11 89 11 92 8 88 6 90 4 87 7
Win/loss counts for all ten random folds for extended similarites MCSext and ECFPext versus their base similarities MCS and ECFP for the receptor specific decoy sets
DuDset at 1%, 5% and 10% of the database. The extension fingerprint is calculated from all ligands (approach B1).
HMGR, ADA and TK data sets) to extract background
knowledge. The results using variant B2 are given in
Tables 11, 12 and 13.
Testing for the improvement of the extended similarity
compared to the baseline similarity, on average, for a given
data set, we find the following numbers of wins and losses
for a fixed α coefficient of 0.3 weighting the contribution
of the extension of the similarity measure in Table 11
(MCS vs MCSext, approach B2): 8:2 (at 1%), 7:3 (at 5%), 8:2
(at 10%). Similar or even stronger results can be found for
other settings, in particular for retrieving 10% of the com-
pounds: 8:2 on Table 12 (ECFP vs. ECFPext, approach B2),
10:0 on Table 8 (MCS vs. MCSext, approach B1) and 8:2 on
Table 9 (ECFP vs. ECFPext, approach B1).
Checking whether these results are statistically signifi-
cant, we chose one of the weakest significance tests, the
sign test [22], which is based on only one weak assump-
tion, namely the independence of the measurements. The
sign test has a p-value ≤ 0.109 for a result of 8 wins
vs. 2 losses, a p-value ≤ 0.0215 for 9 wins vs. 1 loss,
and even smaller for 10 wins vs. 0 losses. We apply the
sign test to determine whether EF is on average greater
for one method compared to another for a given data
set.
Table 18 Win/loss counts for ten random folds for extended similarites on DuD set (α = 0.3; approach B2)
ECFPext MCSext
1% 5% 10% 1% 5% 10%
Win Loss Win Loss Win Loss Win Loss Win Loss Win Loss
HMGR 10 0 9 1 9 1 5 0 5 0 5 0
ER 8 2 9 1 7 3 10 0 9 1 7 3
PPARγ 10 0 9 1 9 1 6 4 10 0 8 2
P38 MAP 9 1 10 0 9 1 9 1 9 1 10 0
TK 7 3 9 1 9 1 9 1 6 4 7 3
FXa 10 0 7 3 8 2 9 1 8 2 8 2
ADA 10 0 6 4 9 1 6 3 8 1 6 3
DHFR 7 3 10 0 10 0 10 0 10 0 10 0
ACHE 8 2 9 1 9 1 8 2 10 0 9 1
COX-2 8 2 9 1 7 3 7 3 8 2 8 2
Sum 87 13 87 13 86 14 79 15 83 11 78 16
Win/loss counts for all ten random folds for extended similarites MCSext and ECFPext versus their base similarities MCS and ECFP for the receptor specific decoy sets
DuDset at 1%, 5% and 10% of the database. The extension fingerprint is calculated from 10% (20% for HMGR, TK and ADA) of the ligands (approach B2).
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Table 19 Win/loss counts for all random folds for extended similarites on DuD set (α ∈ (0.0, 0.1); approach B1)
ECFPext MCSext
1% 5% 10% 1% 5% 10%
Win Loss Win Loss Win Loss Win Loss Win Loss Win Loss
HMGR 102 8 110 0 110 0 48 7 51 4 55 0
ER 70 40 98 12 99 11 97 13 109 1 103 7
PPARγ 93 17 78 32 86 24 94 16 90 20 77 33
P38 MAP 102 8 104 6 104 6 103 7 105 5 100 10
TK 96 14 99 11 92 18 96 14 97 13 99 11
FXa 101 9 100 10 94 16 104 6 100 10 100 10
ADA 91 19 89 21 109 1 81 18 96 3 84 15
DHFR 74 36 110 0 110 0 104 6 110 0 110 0
ACHE 93 17 100 10 101 9 96 14 105 5 101 9
COX-2 57 53 60 50 90 20 78 32 86 24 100 10
Sum 879 221 948 152 995 105 901 133 949 85 929 105
Win/loss counts for all 110 random folds (10 repetitions * 11 αs) for extended similarites MCSext and ECFPext versus their base similarities MCS and ECFP for the
receptor specific decoy sets DuDset at 1%, 5% and 10% of the database. The extension fingerprint is calculated from all ligands (approach B1).
While the results already show improvements of the
score for a fixed α of 0.3, one might be interested in the
results for an optimal α, which we do not know before-
hand. Also, it is interesting to know into which range
optimal αs fall and whether 0.3 is a suitable default value.
Results are shown in Tables 14, 15 and 16 as well as in
Figures 19 and 20. As it turns out, the statistics of the
number of wins and losses can still be improved, e.g., from
8:2, 7:3, 8:2 to 10:0, 9:0, 9:1, respectively, and so forth.
On the other hand, the optimal αs seem to vary some-
what, with a value of 0.3 not being too large for most
data sets and most percentages of retrieved compounds
(see Table 14).
To account for the variation of EF across different sets
within a cross-validation (see the standard deviations in
Tables 8, 9, 10, 11, 12 and 13), we wanted to check whether
the scores of two compared methods go up or down in a
concerted fashion, or whether this is not the case. For this
purpose, we present the win/loss statistics for a fixed α of
0.3 in Tables 17 and 18. As can be seen in these tables,
the proportion of 8:2 or 9:1 still holds when zooming in
on the individual data sets from Tables 8, 9, 11 and 12.
Table 20 Win/loss counts for all random folds for extended similarites on DuD set (α ∈ (0.0, 0.1); approach B2)
ECFPext MCSext
1% 5% 10% 1% 5% 10%
Win Loss Win Loss Win Loss Win Loss Win Loss Win Loss
HMGR 102 8 88 22 98 12 48 7 49 6 55 0
ER 70 40 74 36 74 36 87 23 89 21 67 43
PPARγ 93 17 86 24 88 22 69 41 95 15 72 38
P38 MAP 93 17 96 14 103 7 93 17 100 10 110 0
TK 75 35 95 15 94 16 96 14 85 25 82 28
FXa 101 9 67 43 80 30 99 11 84 26 83 27
ADA 86 24 79 31 98 12 60 39 88 11 76 23
DHFR 75 35 107 3 110 0 100 10 110 0 110 0
ACHE 86 24 95 15 96 14 87 23 98 12 94 16
COX-2 69 41 76 34 78 32 65 45 86 24 90 20
Sum 850 250 863 237 919 181 804 230 884 150 839 195
Win/loss counts for all 110 random folds (10 repetitions * 11 αs) for extended similarites MCSext and ECFPext versus their base similarities MCS and ECFP for the
receptor specific decoy sets DuDset at 1%, 5% and 10% of the database. The extension fingerprint is calculated from 10% (20% for HMGR, TK and ADA) of the ligands
(approach B2).
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Unfortunately, the results are not independent anymore,
thus, the sign test can no longer be applied.
To investigate if the extension similarity simbind_ fp on its
own is better than the base similarity measures MCS and
ECFP we provide Tables 10 and 13. The results show that
the bind_fp similarity in general is not better on its own
in comparison to the base similarities. Only for 10% of the
database in approach B1 the bind_fp similarity performs
better in the ranking than MCS or ECFP.
Our final results on the DuD data sets concern the ques-
tion whether the method is really sensitive against the
choice of a suitable α. For this purpose, we present the
win/loss statistics for a wide range of α values (from 0.0
to 1.0 with a step size of 0.1), across all the data sets from
cross-validation in Tables 19 and 20. Quite surprisingly,
the choice of a value of α does not appear to have a strong
influence on the win/loss statistics. The proportion of
roughly 8:2 or 9:1 still holds in this experiment. Therefore,
we may conclude that the method is reasonably robust
regarding the choice of a suitable value for α.
Comparing the data mining based extension results for
the HMGR data set (first rows denoted HMGR in Tables 8
and 9) with the by-hand results onHMGR in Table 6 (rows
denoted “lig vs DuDset”), we see that the EF values are
slightly better for the by-hand extension, but both variants
of the data mining based approach are quite competitive.
The ECFPext results of variant B1 are even better than the
by-hand results.
As final experiments to test our data-mining based
approaches B1 and B2 we added 25 ChEMBL activity class
data sets. The results for approach B1 and B2 are given
in Tables 21 and 22 respectively. For those data sets the
win counts over all data sets are 19, 21, 21 and 18, 22,
22 (of 25 maximum possible) for 1%, 5% and 10% of the
Table 21 MeanEF and standard deviation for the experiments on the ChEMBL activity classes (approach B2)
MCS MCSext
CAC 1% 5% 10% 1% 5% 10%
4 50.0 ± 23.1 5.8 ± 5.5 2.2 ± 2.6 40.0 ± 11.1 4.0 ± 3.2 0.0 ± 1.5
9 66.7 ± 14.3 13.3 ± 2.9 6.5 ± 1.4 59.3 ± 17.2 11.1 ± 5.0 5.6 ± 2.8
10 66.0 ± 16.5 13.2 ± 3.3 6.2 ± 1.6 53.3 ± 9.8 6.7 ± 1.5 2.7 ± 0.9
21 80.0 ± 8.2 15.4 ± 2.3 7.4 ± 1.4 80.0 ± 15.8 16.0 ± 2.6 8.0 ± 0.0
35 75.0 ± 9.6 14.2 ± 1.7 7.1 ± 0.8 72.2 ± 11.7 12.2 ± 4.8 1.1 ± 3.2
44 66.4 ± 25.8 9.3 ± 6.3 3.3 ± 3.2 30.1 ± 21.1 6.0 ± 3.5 3.0 ± 1.7
52 71.4 ± 9.8 13.0 ± 2.1 5.6 ± 0.9 70.0 ± 9.7 4.0 ± 0.8 0.0 ± 1.0
54 81.4 ± 10.7 15.4 ± 2.5 7.4 ± 1.5 70.0 ± 16.6 12.1 ± 0.0 0.0 ± 0.0
57 54.0 ± 23.2 9.2 ± 5.7 4.4 ± 2.8 60.0 ± 13.5 3.9 ± 6.9 4.9 ± 1.1
81 82.0 ± 7.9 15.4 ± 1.6 6.7 ± 0.9 80.0 ± 6.7 9.8 ± 1.5 2.0 ± 2.6
86 67.0 ± 18.3 10.2 ± 5.4 4.0 ± 3.0 50.0 ± 17.9 4.0 ± 0.7 5.1 ± 1.4
98 80.0 ± 10.0 14.7 ± 2.4 6.7 ± 1.5 70.0 ± 14.6 6.1 ± 4.9 3.0 ± 1.8
105 72.5 ± 14.9 13.3 ± 4.3 6.6 ± 2.1 88.7 ± 10.1 10.0 ± 2.5 2.9 ± 2.6
113 71.1 ± 7.8 12.9 ± 1.1 5.9 ± 0.6 70.1 ± 6.9 8.4 ± 3.1 1.0 ± 1.4
121 74.0 ± 5.2 14.8 ± 1.0 7.2 ± 0.6 69.9 ± 4.9 13.9 ± 1.2 6.9 ± 1.4
129 65.0 ± 10.0 10.5 ± 1.0 4.8 ± 1.3 50.0 ± 9.9 2.0 ± 0.4 0.9 ± 1.6
152 80.0 ± 12.2 16.0 ± 2.4 8.0 ± 1.2 76.5 ± 17.6 16.0 ± 0.6 8.0 ± 2.6
181 66.0 ± 5.5 9.6 ± 2.6 2.8 ± 0.8 60.0 ± 7.6 4.0 ± 4.7 0.8 ± 1.6
186 80.0 ± 7.1 14.0 ± 2.8 6.0 ± 1.6 20.0 ± 15.6 2.0 ± 3.9 0.0 ± 1.8
195 77.8 ± 11.1 14.7 ± 2.5 5.8 ± 0.9 62.9 ± 4.5 9.6 ± 3.6 4.8 ± 2.6
211 50.0 ± 0.0 10.0 ± 0.0 5.0 ± 0.0 50.0 ± 18.0 0.0 ± 3.7 0.0 ± 1.6
213 77.8 ± 13.6 15.1 ± 2.4 7.1 ± 1.5 74.1 ± 6.3 13.3 ± 0.8 6.7 ± 2.6
230 64.0 ± 19.5 8.4 ± 6.1 3.4 ± 2.9 90.0 ± 20.1 14.0 ± 1.6 0.9 ± 1.4
234 52.0 ± 16.4 10.4 ± 3.3 5.2 ± 1.6 40.0 ± 15.5 6.2 ± 2.7 1.0s ± 1.6
238 66.0 ± 15.2 10.4 ± 4.3 4.8 ± 2.0 70.0 ± 12.0 14.0 ± 4.9 3.1 ± 1.8
w/d/l 19 / 2 / 4 21 / 1 / 3 21 / 1 / 3
MeanEF and standard deviation for the MCS and MCSext similarity methods at 1%, 5% and 10% of the database (ZINC subset). The extension fingerprint is calculated
from 10% of the ligands (approach B2). Improvements of MCSext compared to MCS are marked in bold print. CAC = ChEMBL activity class. w/d/l = wins/draws/losses.
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Table 22 MeanEF and standard deviation for the experiments on the ChEMBL activity classes (approach B2)
ECFP ECFPext
CAC 1% 5% 10% 1% 5% 10%
4 46.0 ± 17.1 6.2 ± 3.7 1.6 ± 1.3 30.0 ± 9.9 4.0 ± 4.9 0.0 ± 0.0
9 65.4 ± 13.0 12.1 ± 2.5 5.3 ± 1.6 59.3 ± 9.7 11.1 ± 4.7 5.2 ± 3.2
10 66.0 ± 11.7 11.0 ± 3.3 4.9 ± 1.5 46.7 ± 10.3 6.1 ± 3.9 1.9 ± 1.3
21 66.0 ± 17.8 12.2 ± 3.7 5.8 ± 1.8 49.9 ± 17.8 8.0 ± 2.5 3.0 ± 0.0
35 44.4 ± 25.1 6.7 ± 6.3 2.8 ± 2.7 66.7 ± 11.6 5.6 ± 2.3 0.0 ± 1.3
44 70.0 ± 12.5 12.8 ± 3.3 5.7 ± 1.7 39.4 ± 14.3 8.0 ± 2.5 4.1 ± 1.8
52 71.0 ± 11.0 11.0 ± 2.4 4.4 ± 1.1 39.6 ± 16.5 0.0 ± 3.3 0.0 ± 0.8
54 74.0 ± 11.7 12.4 ± 4.1 5.3 ± 1.9 60.0 ± 10.5 7.6 ± 1.6 1.9 ± 1.5
57 59.0 ± 17.3 10.0 ± 3.9 3.9 ± 2.1 50.0 ± 12.5 2.0 ± 0.9 0.8 ± 2.2
81 77.0 ± 6.7 14.2 ± 1.5 6.5 ± 1.0 80.0 ± 11.0 12.0 ± 2.6 3.6 ± 1.5
86 55.0 ± 17.2 7.4 ± 4.4 2.6 ± 2.0 70.0 ± 11.7 6.0 ± 4.8 1.0 ± 1.8
98 60.0 ± 22.1 11.2 ± 4.3 5.5 ± 2.3 40.0 ± 25.8 6.0 ± 3.3 3.0 ± 1.0
105 58.0 ± 24.9 10.8 ± 4.6 5.2 ± 2.2 60.0 ± 9.8 10.0 ± 2.4 4.0 ±s 0.0
113 64.0 ± 10.8 10.0 ± 3.4 4.2 ± 1.8 50.0 ± 7.9 2.1 ± 2.6 0.9 ± 2.6
121 74.0 ± 5.2 14.6 ± 1.0 6.5 ± 0.8 70.0 ± 10.7 14.0 ± 2.4 6.8 ± 1.6
129 69.0 ± 9.9 12.4 ± 1.6 5.5 ± 1.5 49.8 ± 23.2 6.0 ± 4.3 0.8 ± 1.3
152 74.0 ± 12.6 14.6 ± 2.5 6.9 ± 1.5 90.0 ± 13.3 14.2 ± 0.7 4.2 ± 1.7
181 61.0 ± 12.9 10.6 ± 3.0 4.7 ± 1.6 39.8 ± 24.9 7.8 ± 4.9 3.0 ± 1.9
186 60.0 ± 14.9 7.4 ± 4.6 2.6 ± 1.7 20.1 ± 13.6 2.0 ± 2.5 0.0 ± 2.1
195 69.1 ± 14.5 12.3 ± 2.7 5.7 ± 1.4 59.3 ± 19.5 11.1 ± 3.3 4.8 ± 1.8
211 42.0 ± 9.2 7.8 ± 2.9 3.1 ± 1.4 19.8 ± 12.6 0.0 ± 1.2 0.0 ± 2.6
213 61.7 ± 13.7 9.4 ± 2.2 3.7 ± 1.1 55.6 ± 20.2 10.4 ± 0.4 5.2 ± 1.4
230 60.0 ± 18.3 10.2 ± 3.6 3.3 ± 1.3 90.0 ± 17.8 11.9 ± 3.6 2.0 ± 1.4
234 57.0 ± 17.0 8.4 ± 3.9 3.2 ± 1.7 41.2 ± 14.9 2.0 ± 4.7 1.1 ± 1.6
238 64.0 ± 17.8 11.8 ± 3.9 5.0 ± 1.9 80.0 ± 14.5 16.3 ± 1.6 7.0 ± 1.8
w/d/l 18 / 0 / 7 22 / 0 / 3 22 / 0 / 3
MeanEF and standard deviation for the ECFP and ECFPext similarity methods at 1%, 5% and 10% of the database (ZINC subset). The extension fingerprint is calculated
from 10% of the ligands (approach B2). Improvements of MCSext compared to MCS are marked in bold print. CAC = ChEMBL activity class. w/d/l = wins/draws/losses.
database and MCSext and ECFPext . According to the sign
test the difference between extended and non-enxtended
similarities is significant at a level of 0.05 [22].
Conclusions
Structural similarity measures, especially the ECFP fin-
gerprints, have been reported to be superior to non-
substructural fingerprints [23]. This work shows that
and how such structural similarity methods used in vir-
tual screening can be improved further by integrating
background knowledge on binding-relevant structural
features. We presented an approach based on by-hand
selection of the background knowledge as well as an
approach working with fragment-based data mining.
From our experimental evaluation we conclude that
the addition of only one binding-relevant sub-structural
feature of a known ligand can substantial improve the
enrichment factors in the virtual screening. We addi-
tionally show that using data mining based knowledge
extraction instead of time consuming by-hand selection of
relevant features gives competitive results.
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